[Federal Register: July 9, 2007 (Volume 72, Number 130)]
[Notices]
[Page 37242-37243]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr09jy07-73]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N-0240]
Agency Information Collection Activities; Proposed Collection;
Comment Request, Patent Term Restoration, Due Diligence Petitions,
Filing, Format, and Content of Petitions
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on FDA's patent term restoration
regulations on due diligence petitions for regulatory review period
revision. Where a patented product must receive FDA approval before
marketing is permitted, the Office of Patents and Trademarks may add a
portion of the FDA review time to the term of a patent. Petitioners may
request reductions in the regulatory review time if FDA marketing
approval was not pursued with ``due diligence.''
DATES: Submit written comments on the collection of information by
September 7, 2007.
ADDRESSES: Submit electronic comments on the collection of information
to: http://www.fda.gov/dockets/ecomments. Submit written comments on
the collection of information to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of the
Chief Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice
[[Page 37243]]
of the proposed collection of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Patent Term Restoration, Due Diligence Petitions, Filing, Format, and
Content of Petitions--21 CFR Part 60 (OMB Control Number 0910-0233--
Extension)
FDA's patent extension activities are conducted under the authority
of the Drug Price Competition and Patent Term Restoration Act of 1984
(21 U.S.C. 355(j)) and the Animal Drug and Patent Term Restoration Act
of 1988 (35 U.S.C. 156). New human drug, animal drug, human biological,
medical device, food additive, or color additive products regulated by
FDA must undergo FDA safety, or safety and effectiveness, review before
marketing is permitted. Where the product is covered by a patent, part
of the patent's term may be consumed during this review, which
diminishes the value of the patent. In enacting the Drug Price
Competition and Patent Term Restoration Act of 1984 and the Animal Drug
and Patent Term Restoration Act of 1988, Congress sought to encourage
development of new, safer, and more effective medical and food additive
products. It did so by authorizing the U.S. Patent and Trademark Office
(PTO) to extend the patent term by a portion of the time during which
FDA's safety and effectiveness review prevented marketing of the
product. The length of the patent term extension is generally limited
to a maximum of 5 years, and is calculated by PTO based on a statutory
formula. When a patent holder submits an application for patent term
extension to PTO, PTO requests information from FDA, including the
length of the regulatory review period for the patented product. If PTO
concludes that the product is eligible for patent term extension, FDA
publishes a notice that describes the length of the regulatory review
period and the dates used to calculate that period. Interested parties
may request, under Sec. 60.24 (21 CFR 60.24), revision of the length
of the regulatory review period, or may petition under Sec. 60.30 (21
CFR 60.30) to reduce the regulatory review period by any time where
marketing approval was not pursued with ``due diligence.'' The statute
defines due diligence as ``that degree of attention, continuous
directed effort, and timeliness as may reasonably be expected from, and
are ordinarily exercised by, a person during a regulatory review
period.'' As provided in Sec. 60.30(c), a due diligence petition
``shall set forth sufficient facts, including dates if possible, to
merit an investigation by FDA of whether the applicant acted with due
diligence.'' Upon receipt of a due diligence petition, FDA reviews the
petition and evaluates whether any change in the regulatory review
period is necessary. If so, the corrected regulatory review period is
published in the Federal Register. A due diligence petitioner not
satisfied with FDA's decision regarding the petition may, under Sec.
60.40 (21 CFR 60.40), request an informal hearing for reconsideration
of the due diligence determination. Petitioners are likely to include
persons or organizations having knowledge that FDA's marketing
permission for that product was not actively pursued throughout the
regulatory review period. The information collection for which an
extension of approval is being sought is the use of the statutorily
created due diligence petition.
Since 1992, nine requests for revision of the regulatory review
period have been submitted under Sec. 60.24. Four regulatory review
periods have been altered. Two due diligence petitions have been
submitted to FDA under Sec. 60.30. There have been no requests for
hearings under Sec. 60.40 regarding the decisions on such petitions.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
60.24(a) 9 1 9 100 900
----------------------------------------------------------------------------------------------------------------
60.30 2 0 2 50 100
----------------------------------------------------------------------------------------------------------------
60.40 0 0 0 0 0
----------------------------------------------------------------------------------------------------------------
Total 1,000
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: June 28, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-13269 Filed 7-6-07; 8:45 am]
BILLING CODE 4160-01-S